Cardiovascular clinical research

Researchers

  • Alba Oliveras

    Cardiovascular clinical research

  • Anna Contra Carne

    Cardiovascular clinical research

  • Antonio Carol Ruiz

    Cardiovascular clinical research

  • Antonia Ortega Díaz

    Cardiovascular clinical research

  • Carlos Enrique Sabbagh Fajardo

    Cardiovascular clinical research

  • carmen martin

    Cardiovascular clinical research

  • Elizabeth Mena Sebastià

    Cardiovascular clinical research

  • Joan Pol Monteys Montblanch

    Cardiovascular clinical research

  • José Navarrete Monte

    Cardiovascular clinical research

  • Maria Del Señor Cortés Fernández

    Cardiovascular clinical research

  • Marta Camprecios Crespo

    Cardiovascular clinical research

  • Mercè Faraudo

    Cardiovascular clinical research

  • Miriam Garcia Bermudez

    Cardiovascular clinical research

  • Olga Guri

    Cardiovascular clinical research

  • Peter Castellanos

    Cardiovascular clinical research

  • Pilar Sánchez Chamero

    Cardiovascular clinical research

    Phd
  • Raúl Lafuente Masqueda

    Cardiovascular clinical research

  • Román Freixa Pamías

    Cardiovascular clinical research

    Phd
  • Sandra Lara Sanmartin

    Cardiovascular clinical research

Contact the group

Form
  • Riera-Mestre A, Camafort M, Suriñach JM, Muñoz Rodriguez FJ, Padilla F, Francisco-Pascual J, Arranz JM, Martinez Rubio A, Villuendas Sabaté R, Freixa-Pamias R, Suarez C, Santamaría A. 204/20

    Anticoagulation of the multipathological elderly patient with non-valvular atrial fibrillation: role of rivaroxaban.

    Rev Esp Cardiol Suppl. 2020;19(A):3-10
  • de Frutos F, Mirabet S, Ortega-Paz L, Buera I, Darnés S, Farré N, Andrés B, Adeliño R, Bascompte R, Pérez-Rodón J, Aparicio X, Sutil-Vega M, Soto A, Faraudo M, Cainzos - Achirica M, and Manito N. 260/20

    Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry.

    ESC Heart Fail. 2020 Feb;7(1):25-35.
  • Yun S, Enjuanes C, Calero E, Hidalgo E, Cobo M, Llàcer P, García-Pinilla JM, González-Franco A, Núñez J, Morales-Rull JL, Beltrán P, Delso C, Freixa R, Moliner P, Corbella X , Comín-Colet J, HERMeS trial investigators group. 312/20

    Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS).

    ESC Heart Fail. 2020 Sep 17
  • Garcimartín P, Comín-Colet J, Pardo-Cladellas Y, Badosa N, Linas A, Rosenfeld L, Faraudo M, et al. 325/20

    Validation of the Spanish version of the questionnaire on Patient Empowerment in Long-Term Conditions.

    PLoS One. 2020 Jun 12; 15 (6): e0233338.
  • Freixa-Pamias R, Blanch Gràcia P, Rodríguez Latre ML, Basile L, Sánchez Chamero P, Gómez-Choco M, Armario P, Martínez-Rubio A, Lupón J; Working Group for coordination between Cardiology & Primary Care, Barcelona, ​​Spain. 251/20

    Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke.

    Curr Med Res Opin. 2020 Dec 16; 1
  • Bonanad Lozano C, Díez-Villanueva P, García Blas S, Ayesta A, Ibars S, Ariza-Solé A, Ferreiro L, Moreno R, Roldán I, Marín F, Carol Ruiz A, García Pardo H, Sanchís J, Cruz-González I, Anguita M, Cequier A, Ruiz García J, Martínez-Sellés M. 248/20

    Impact of antithrombotic treatment and geriatric syndromes in octogenarians with atrial fibrillation and ischemic heart disease. Atrial Fibrillation and Ischemic Heart Disease in the Elderly.

  • Anguita M, Bayés-Genís A, Cepeda JM, Cinza S, Cosín J, CrespoLeire M, Egocheaga I, Faraudo M, Garcia-Pinilla JM, Manzano L, Obaya JC, PascualFigal D, Segovia-Cubero J, Loza E. 216/ 20

    Expert consensus on heart failure with reduced ejection fraction: beyond the guidelines.

    1-3587(20)30016-9
  • Cosin-Sales J, Freixa R, Bravo M, Ruvira J, Blanch P, Calvo Iglesias FE, Escobar C. 250/20

    Impact of different models of improvement of continuity of care on lipid control and the delay of visits to cardiology.

    Future Cardiol. 2020 Jan;16(1):33-41
  • Mena Sebastiá E, Tirapu Sola L, Villanueva Vázquez R, Losa Gaspà F, Freixa-Pamias R. 210/20

    Cancer, onco-hematological treatment and cardiovascular toxicity.

    Vasc Hypertensive Risk 2020 Sep 23;S1889-1837(20)30083-0
  • Cortés Fernández MS, Monteys JP, Castellanos P, Armario P. 245/20

    Malignant arterial hypertension (HTAM) with severe reversible left ventricular systolic dysfunction.

    Vasc Hypertensive Risk Apr-Jun 2020;37(2):82-85.

Projects

    • Year 2020
    • HSDMB

    Prospective Observational Register of Patients with Heart Failure.

    • DISTRICT ATTORNEY:

      Spanish Society of Cardiology (SEC)

    • TYPE E:

      EPA-SP

    • Year 2020
    • HSDMB

    Treatment of dyslipidemic patients with high risk and very high risk for the prevention of cardiovascular events in Europe - Multinational Observational Study (SANTORINI).

    • DISTRICT ATTORNEY:

      Daiichi Sankyo Europe GmbH

    • TYPE E:

      EPA-SP

    • Year 2020
    • HSDMB

    Observational study to evaluate the Net Clinical Benefit of Edoxaban in patients with non-valvular atrial fibrillation, according to usual clinical practice in Spain. BENEFIT Registry.

    • DISTRICT ATTORNEY:

      Daiichi Sankyo Spain, SAU

    • TYPE E:

      EPA-OD

    • Year 2020
    • HSDMB

    Behavior of edoxaban in patients with non-valvular atrial fibrillation and heart failure in Spain - Behavior of edoxaban in LVEF and HF. I study EMAYIC.

    • DISTRICT ATTORNEY:

      Spanish Society of Cardiology (SEC)

    • TYPE E:

      EPA-SP

    • Year 2020
    • HSDMB

    A Multicenter, Randomized, Double-Blind, and 90-Day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety, and Tolerability of Empagliflozin 10 Mg Once a Day Oral Compared to Placebo, Started in Patients Hospitalized for Acute Heart Failure (De Novo or Chronic Decompensated Ic) Who Have Been Stabilized (Impulse),

    • DISTRICT ATTORNEY:

      Boehringer Ingelheim International GmbH

    • TYPE E:

      RD2015

    • Year 2020
    • HSDMB

    Prospective, double-blind, randomized, parallel and placebo-controlled pilot clinical trial for the evaluation of the efficacy and safety of two doses of MSC, WJ in patients with acute respiratory distress syndrome secondary to infection by COVID-19.

    • DISTRICT ATTORNEY:

      Blood and Tissue Bank

    • TYPE E:

      RD2015

    • Year 2020
    • HSDMB

    A Multicenter, Randomized, Double-Blind, and 90-Day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety, and Tolerability of Empagliflozin 10 Mg Once a Day by Oral Way Compared to Placebo, Started in Patients Hospitalized for Acute Heart Failure ( De Novo or Chronic Decompensated Ic) Who Have Been Stabilized (Impulse),

    • DISTRICT ATTORNEY:

      Boehringer Ingelheim International GmbH

    • TYPE E:

      RD2015

    • Year 2020
    • HSDMB

    Prospective, double-blind, randomized, parallel and placebo-controlled pilot clinical trial for the evaluation of the efficacy and safety of two doses of MSC, WJ in patients with acute respiratory distress syndrome secondary to infection by COVID-19.

    • DISTRICT ATTORNEY:

      Blood and Tissue Bank

    • TYPE E:

      RD2015

    • Year 2020
    • HSDMB

    Prospective Observational Register of Patients with Heart Failure.

    • DISTRICT ATTORNEY:

      Spanish Society of Cardiology (SEC)

    • TYPE E:

      EPA-SP

    • Year 2020
    • HSDMB

    Treatment of dyslipidemic patients with high risk and very high risk for the prevention of cardiovascular events in Europe - Multinational Observational Study (SANTORINI).

    • DISTRICT ATTORNEY:

      Daiichi Sankyo Europe GmbH

    • TYPE E:

      EPA-SP

Lines of action

  • Self control in carriers Mechanical prosthesis
  • Cryptogenetic stroke
  • Spontaneous coronary dissection
  • Atrial fibrillation, anticoagulation and stroke / bleeding
  • Integrated cardiology primary care
  • LDL control in post-SCA patients
  • Impact of IC Functional Unit on Hospital Admissions / Re-admissions

Documents

Information of interest

Links